Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2020-12-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. SAPIENT = Sepsis ACLF patients, to investigate the differences between ACLF and sepsis in cirrhosis
2. PROACT = Portal mediators as ACLF Targets, to assess portal venous biomarkers in patients receiving TIPS leading to ACLF and identify potential treatment targets
3. ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts, to assess in ACLF-patients receiving liver transplantation predictors of survival, which may improve selection of ACLF-patients for liver transplantation Secondary endpoints will be different in the three different cohorts and biological material will be collected for separate ancillary studies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
NCT04578301
The European NAFLD Registry
NCT04442334
Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease
NCT02488941
Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis
NCT03746210
Prospective Cohort Study in Patients With NAFLD
NCT00575133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SAPIENT = Sepsis ACLF patients
No interventions assigned to this group
PROACT = Portal mediators as ACLF Targets
No interventions assigned to this group
ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* refusal for participation
* decision of attending phycisian
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonel Trebicka
Principal Investigator and Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonel Trebicka, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Goethe University Hospital Frankfurt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Translational Hepatology
Frankfurt am Main, Hesse, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jonel Trebicka
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACLF-Initiative
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.